Abstract:Arenaviruses are a large family of emerging enveloped negative-strand RNA viruses that include several causative agents of viral hemorrhagic fevers. For cell entry, human-pathogenic arenaviruses use different cellular receptors and endocytic pathways that converge at the level of acidified late endosomes, where the viral envelope glycoprotein mediates membrane fusion. Inhibitors of arenavirus entry hold promise for therapeutic antiviral intervention and the identification of "druggable" targets is of high priority. Using a recombinant vesicular stomatitis virus pseudotype platform, we identified the clotrimazole-derivative TRAM-34, a highly selective antagonist of the calcium-activated potassium channel KCa3.1, as a specific entry inhibitor for arenaviruses. TRAM-34 specifically blocked entry of most arenaviruses, including hemorrhagic fever viruses, but not Lassa virus and other enveloped viruses. Anti-arenaviral activity was likewise observed with the parental compound clotrimazole and the derivative senicapoc, whereas structurally unrelated KCa3.1 inhibitors showed no antiviral effect. Deletion of KCa3.1 by CRISPR/Cas9 technology did not affect the antiarenaviral effect of TRAM-34, indicating that the observed antiviral effect of clotrimazoles was independent of the known pharmacological target. The drug affected neither virus-cell attachment, nor endocytosis, suggesting an effect on later entry steps. Employing a quantitative cell-cell fusion assay that bypasses endocytosis, we demonstrate that TRAM-34 specifically inhibits arenavirus-mediated membrane fusion. In sum, we uncover a novel antiarenaviral action of clotrimazoles that currently undergo in vivo evaluation in the context of other human diseases. Their favorable in vivo toxicity profiles and stability opens the possibility to repurpose clotrimazole derivatives for therapeutic intervention against human-pathogenic arenaviruses.IMPORTANCE Emerging human-pathogenic arenaviruses are causative agents of severe hemorrhagic fevers with high mortality and represent serious public health problems. The current lack of a licensed vaccine and the limited treatment options makes the development of novel antiarenaviral therapeutics an urgent need. Using a recombinant pseudotype platform, we uncovered that clotrimazole drugs, in particular TRAM-34, specifically inhibit cell entry of a range of arenaviruses, including important emerging human pathogens, with the exception of Lassa virus. The antiviral effect was independent of the known pharmacological drug target and involved inhibition of the unusual membrane fusion mechanism of arenaviruses. TRAM-34 and its derivatives currently undergo evaluation against a number of human diseases and show favorable toxicity profiles and high stability in vivo Our study provides the basis for further evaluation of clotrimazole derivatives as antiviral drug candidates. Their advanced stage of drug development will facilitate repurposing for therapeutic intervention against human-pathogenic arenaviruses.

A host-oriented inhibitor of Junin Argentine hemorrhagic fever virus egress.

A Host-Oriented Inhibitor of Junin Argentine Hemorrhagic Fever Virus Egress

Identification and Characterization of a Novel Broad-Spectrum Virus Entry Inhibitor

Novel neutralizing monoclonal antibodies against Junin virus.

Structural Basis for Recognition and Regulation of Arenavirus Polymerase L by Z Protein

Crystal Structure of Junin Virus Nucleoprotein

Immunization with GP1 but Not Core-like Particles Displaying Isolated Receptor-Binding Epitopes Elicits Virus-Neutralizing Antibodies against Junín Virus

The roles of XJ13 and XJ44-specific mutations within the Candid #1 GPC in Junin virus attenuation

Cathelicidin-Derived Antimicrobial Peptides Inhibit Zika Virus Through Direct Inactivation and Interferon Pathway.

Small-Molecule Probes Targeting the Viral Ppxy-Host Nedd4 Interface Block Egress of A Broad Range of Rna Viruses

Identification of a novel compound targeting the nuclear export of influenza A virus nucleoprotein.

Vaccine-elicited receptor-binding site antibodies neutralize two New World hemorrhagic fever arenaviruses

RIG-I enhanced interferon independent apoptosis upon Junin virus infection

Screening and Identification of Lujo Virus Entry Inhibitors From an Food and Drug Administration-Approved Drugs Library

Blockade of Pan-Viral Propagation by Inhibition of Host Cell PNPT1.

Potent Inhibition of Zika Virus Replication by Aurintricarboxylic Acid

Pan-viral propagation blockade by inhibiting host cell PNPT1

Identification of a Small Compound That Specifically Inhibits Zika Virus in Vitro and in Vivo by Targeting the NS2B-NS3 Protease

Pan-serotype dengue virus inhibitor JNJ-A07 targets NS4A-2K-NS4B interaction with NS2B/NS3 and blocks replication organelle formation

Identification of Clotrimazole Derivatives as Specific Inhibitors of Arenavirus Fusion

Development of NS2B-NS3 protease inhibitor that impairs Zika virus replication